Funding for this research was provided by:
UK Dementia Research Institute
Received: 20 July 2020
Accepted: 4 December 2020
First Online: 13 January 2021
: N.G., D.W. and E.S.B. have applied for a patent on the ecHT technology, assigned to MIT, and founded a company that utilises it. K.P.B., received funding for travel from GlaxoSmithKline, Orion Corporation, Ipsen, and Merz Pharmaceuticals, LLC; serves on the editorial boards of Movement Disorders and Therapeutic Advances in Neurological Disorders; receives royalties from the publication of Oxford Specialist Handbook of Parkinson’s Disease and Other Movement Disorders (Oxford University Press, 2008); received speaker honoraria from GlaxoSmithKline, Ipsen, Merz Pharmaceuticals, LLC, and Sun Pharmaceutical Industries Ltd.; personal compensation for scientific advisory board for GSK and Boehringer Ingelheim; received research support from Ipsen and from the Halley Stewart Trust through Dystonia Society UK. The rest of the authors declare no competing interests.